
REZOLUTE




11 July 2020

CHI Program Updates

RZ358

RZ358 Has the Potential to Address Limitations of SOC



	Current Standard of Care	RZ358
Targeting	<p>— Beta cells only</p>	<p>+ Insulin receptor/signal on insulin-dependent target organs</p>
Development	<p>— Not developed for congenital HI</p>	<p>+ Tailored for congenital HI</p>
Impact	<p>— Marginally effective, invasive, and/or significant AEs</p>	<p>+ Reversibly counteracts insulin only when insulin is elevated</p>
Relevancy	<p>— Genetics-dependent narrow targeting</p>	<p>+ Potentially universal treatment</p>


RZ358 Clinical Experience

- 59 participants have received RZ358 in clinical studies conducted to date, including 5 pediatric patients with CHI
- Safe and well tolerated overall, no identified safety risks thus far
- In 14 CHI patients, single doses of RZ358 improved hypoglycemia and maintained normal glucose (without hyperglycemia) for a persistent period of ~ 2-4 weeks
- Data support potential 2x/monthly or even monthly 30 min IV infusion

Visit our Virtual Booth for more information on previously conducted studies with RZ358

Phase 2b Study Design (RIZE)

RZ358-606



Treatment Period and Study Assessment Tools




All eligible patients will be provided with a **real-time (unblinded) Dexcom G6 Continuous Glucose Monitor**



Self-monitored blood glucometer will be used and can be provided to the patients to use throughout the study.




Patients will use an eDiary (via provided I-phone) to record daily glucose events and any changes in diet and exercise.



Blood samples will be taken and analyzed throughout the study to determine the optimal dose for Phase 3.

RIZE Study Clinical Timelines

RZ358-606



Rezolute Clinical Operations Team and Virtual Booth Contacts

Brian Roberts

Head of Clinical Development

Medical Monitor for the RIZE study.

Malathi Robaina

Director of Clinical Operations

Malathi leads the US RIZE study activities.

Loredie Lugos

Associate Director of Clinical Operations

Loredie leads the Ex-US RIZE study activities.

Bob Sala and Stefania Guerra

Dexcom – Scientific Medical Expert

Both are working with the Rezolute team to provide training and education to the sites and patients.

Please stop by our virtual booth to meet the **RIZE**
RZ358-606 study team and see other company presentations.

Erin O'Boyle – Head of Clinical Operations